Interactions of host IL-6 and IFN-γ and cancer-derived TGF-β1 on MHC molecule expression during tumor spontaneous regression

Cancer Immunology, Immunotherapy

Volumn 57, Issue 7, 2008, Pages 1091-1104

  Hsiao, Ya Wen ^a,b   Liao, Kuang Wen ^c   Chung, Tien Fu ^a   Liu, Chen Hsuan ^a   Hsu, Chia Da ^a   Chu, Rea Min ^a,d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^d Cancer Research Center   (Taiwan)

Author keywords

IFN ; IL 6; MHC; TGF 1; Transcription factors

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN; NEUTRALIZING ANTIBODY; STAT1 PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANIMAL VENEREAL TUMOR; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; DOG; FEMALE; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALS; DOG DISEASES; DOGS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERFERON TYPE II; INTERLEUKIN-6; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; NEOPLASM REGRESSION, SPONTANEOUS; PROTEIN BINDING; TRANSFORMING GROWTH FACTOR BETA1; VENEREAL TUMORS, VETERINARY;

EID: 42649145837     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0446-5     Document Type: Article

References (58)

1. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89-95
2. Hoffmann TK, Meidenbauer N, Muller-Berghaus J, Storkus WJ, Whiteside TL (2001) Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. J Immunother 24:162-171
3. Overwijk WW (2005) Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol 17:187-194
4. Yu Z, Restifo NP (2002) Cancer vaccines: progress reveals new complexities. J Clin Invest 110:289-294
5. Murgia C, Pritchard JK, Kim SY, Fassati A, Weiss RA (2006) Clonal origin and evolution of a transmissible cancer. Cell 126:477-487
6. Hsiao YW, Liao KW, Hung SW, Chu RM (2002) Effect of tumor infiltrating lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells. Vet Immunol Immunopathol 87:19-27
7. Katzir N, Arman E, Cohen D, Givol D, Rechavi G (1987) Common origin of transmissible venereal tumors (TVT) in dogs. Oncogene 1:445-448
8. Liao KW, Lin ZY, Pao HN, Kam SY, Wang FI, Chu RM (2003) Identification of canine transmissible venereal tumor cells using in situ polymerase chain reaction and the stable sequence of the long interspersed nuclear element. J Vet Diagn Invest 15:399-406
9. Hsiao YW, Liao KW, Hung SW, Chu RM (2004) Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. J Immunol 172:1508-1514
10. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA (2006) Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24:99-146
11. Cross D, Cambier JC (1990) Transforming growth factor beta 1 has differential effects on B cell proliferation and activation antigen expression. J Immunol 144:432-439
12. Thomas DA, Massague J (2005) TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8:369-380
13. Panek RB, Lee YJ, Benveniste EN (1995) TGF-beta suppression of IFN-gamma-induced class II MHC gene expression does not involve inhibition of phosphorylation of JAK1, JAK2, or signal transducers and activators of transcription, or modification of IFN-gamma enhanced factor X expression. J Immunol 154:610-619
14. Ljunggren G, Anderson DJ (1998) Cytokine induced modulation of MHC class I and class II molecules on human cervical epithelial cells. J Reprod Immunol 38:123-138
15. Ting JP, Baldwin AS (1993) Regulation of MHC gene expression. Curr Opin Immunol 5:8-16
16. Wei L-H, Kuo M-L, Chen C-A, Chou C-H, Lai K-B, Lee C-N, Hsieh C-Y (2003) Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22:1517
17. Ohta K, Yamagami S, Taylor AW, Streilein JW (2000) IL-6 antagonizes TGF-beta and abolishes immune privilege in eyes with endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 41:2591-2599
18. Rabinowich H, Sedlmayr P, Herberman RB, Whiteside TL (1993) Response of human NK cells to IL-6 alterations of the cell surface phenotype, adhesion to fibronectin and laminin, and tumor necrosis factor-alpha/beta secretion. J Immunol 150:4844-4855
19. Scheid C, Young R, McDermott R, Fitzsimmons L, Scarffe JH, Stern PL (1994) Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunol Immunother 38:119-126
20. Cao X, Wang Q, Ju DW, Tao Q, Wang J (1999) Efficient inducation of local and systemic antitumor immune response by liposome-mediated intratumoral co-transfer of interleukin-2 gene and interleukin-6 gene. J Exp Clin Cancer Res 18:191-200
21. Liang CT, Chueh LL, Pang VF, Zhuo YX, Liang SC, Yu CK, Chiang H, Lee CC, Liu CH (2007) A non-biotin polymerized horseradish-peroxidase method for the immunohistochemical diagnosis of canine distemper. J Comp Pathol 136:57-64
22. Wagner AH, Gebauer M, Pollok-Kopp B, Hecker M (2002) Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1. Blood 99:520-525
23. Park YG, Nesterova M, Agrawal S, Cho-Chung YS (1999) Dual blockade of cyclic AMP response element- (CRE) and AP-1-directed transcription by CRE-transcription factor decoy oligonucleotide. gene-specific inhibition of tumor growth. J Biol Chem 274:1573-1580
24. Krzesz R, Wagner AH, Cattaruzza M, Hecker M (1999) Cytokine-inducible CD40 gene expression in vascular smooth muscle cells is mediated by nuclear factor kappaB and signal transducer and activation of transcription-1. FEBS Lett 453:191-196
25. Darnell JE, Kerr I, Stark G (1994) Jak-STAT pathways and transcriptional activation in response to interferons and other extracellular signaling proteins. Science 264:1415-1420
26. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334(Pt 2):297-314
27. Ehret GB, Reichenbach P, Schindler U, Horvath CM, Fritz S, Nabholz M, Bucher P (2001) DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J Biol Chem 276:6675-6688
28. Pazmany T, Tomasi TB (2006) The major histocompatibility complex class II transactivator is differentially regulated by interferon-gamma and transforming growth factor-beta in microglial cells. J Neuroimmunol 172:18-26
29. Ma D, Niederkorn JY (1995) Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology 86:263-269
30. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D et al (1992) Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359:693-699
31. McCartney-Francis NL, Wahl SM (2002) Dysregulation of IFN-gamma signaling pathways in the absence of TGF-beta 1. J Immunol 169:5941-5947
32. Geiser AG, Letterio JJ, Kulkarni AB, Karlsson S, Roberts AB, Sporn MB (1993) Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype. Proc Natl Acad Sci USA 90:9944-9948
33. Shouda T, Hiraoka K, Komiya S, Hamada T, Zenmyo M, Iwasaki H, Isayama T, Fukushima N, Nagata K, Yoshimura A (2006) Suppression of IL-6 production and proliferation by blocking STAT3 activation in malignant soft tissue tumor cells. Cancer Lett 231:176-184
34. Mule JJ, Custer MC, Travis WD, Rosenberg SA (1992) Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immunol 148:2622-2629
35. Usuda J, Okunaka T, Furukawa K, Tsuchida T, Kuroiwa Y, Ohe Y, Saijo N, Nishio K, Konaka C, Kato H (2001) Increased cytotoxic effects of photodynamic therapy in IL-6 gene transfected cells via enhanced apoptosis. Int J Cancer 93:475-480
36. Code S, Simard C, Lemieux R (2002) Regulation of growth-related genes by interleukin-6 in muring myeloma cells. Cytokine 20:113-120
37. Sakaguichi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6:345-352
38. Wang HY, Wang RF (2007) Regulatory T cells and cancer. Curr Opin Immunol 19:217-223
39. Zhang L, Yi H, Xia XP, Zhao Y (2006) Transforming growth factor-beta: an important role in CD4+CD25+ regulatory T cells and immune tolerance. Autoimmunity 39:269-276
40. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM (2003) Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875-1886
41. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061
42. Shuai K, Liu B (2003) Regulation of JAK-STAT signalling in the immune system. Nat Rev 3:900-911
43. Balhoff JP, Stephens JM (1998) Highly specific and quantitative activation of STATs in 3T3-L1 adipocytes. Biochem Biophys Res Commun 247:894-900
44. Christian M, Marangos P, Mak I, McVey J, Barker F, White J, Brosens JJ (2001) Interferon-gamma modulates prolactin and tissue factor expression in differentiating human endometrial stromal cells. Endocrinology 142:3142-3151
45. Moreno CS, Beresford GW, Louis-Plence P, Morris AC, Boss JM (1999) CREB regulates MHC class II expression in a CIITA-dependent manner. Immunity 10:143-151
46. van der Stoep N, Quinten E, van den Elsen PJ (2002) Transcriptional regulation of the MHC class II trans-activator (CIITA) promoter III: identification of a novel regulatory region in the 5'-untranslated region and an important role for cAMP-responsive element binding protein 1 and activating transcription factor-1 in CIITA-promoter III transcriptional activation in B lymphocytes. J Immunol 169:5061-5071
47. Huang S (2007) Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res 13:1362-1366
48. Bowman T, Garcia R, Turkson J, Jove R (2000) STATs in oncogenesis. Oncogene 19:2474-2488
49. Kortylewski M, Kujawski M, Wang TH, Wei S, Zhang SM, Guilian STP, Kay NHK, William JM, Richard GK, Pardoll JW, Yu H (2005) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11:1314-1321
50. Aggarwal B, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, Sung B, Ichikawa H (2006) Targeting signal-transducer-and-activator-of-transcription- 3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 1091:151-169
51. Wagenka UM, Buschmann L, Lutticken C, Heinrich PC, Horn F (1993) Acute-phase response factor, a muclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol 13:2762-2788
52. Revel M, Katz A, Eisenbach L, Feldman M, Haran-Ghera N, Harroch S, Chebath J (1995) Interleukin-6: effects on tumor models in mice and on the cellular regulation of transcription factor IRF-1. Ann N Y Acad Sci 762:342-355; Discussion 355-346
53. Agresti C, Bernardo A, Del Russo N, Marziali G, Battistini A, Aloisi F, Levi G, Coccia EM (1998) Synergistic stimulation of MHC class I and IRF-1 gene expression by IFN-gamma and TNF-alpha in oligodendrocytes. Eur J Neurosci 10:2975-2983
54. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD (1996) Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84:431-442
55. Chelbi-alix MK, Bobe P, Benoit G, Canova A, Pine R (2003) Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1. Oncogene 22:9121-9130
56. Wesoly J, Szweykowska-Kulinska Z, Bluyssen HA (2007) STAT activation and differential complex formation dictate selectivity of interferon responses. Acta Biochim Pol 54:27-38
57. Kim OS, Park EJ, Joe EH, Jou I (2002) JAK-STAT signaling mediates gangliosides-induced inflammatory responses in brain microglial cells. J Biol Chem 277:40594-40601
58. Gobin SJ, van Zutphen M, Woltman AM, van den Elsen PJ (1999) Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element. J Immunol 163:1428-1434